Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Debt to Equity (2024 - 2025)

Historic Debt to Equity for Apellis Pharmaceuticals (APLS) over the last 2 years, with Q3 2025 value amounting to $1.13.

  • Apellis Pharmaceuticals' Debt to Equity fell 2513.66% to $1.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.13, marking a year-over-year decrease of 2513.66%. This contributed to the annual value of $1.57 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Debt to Equity of $1.13 as of Q3 2025, which was down 2513.66% from $2.31 recorded in Q2 2025.
  • Apellis Pharmaceuticals' Debt to Equity's 5-year high stood at $2.31 during Q2 2025, with a 5-year trough of $1.13 in Q3 2025.